logo-loader
viewAdvanced Oncotherapy PLC

Advanced Oncotherapy - Holding(s) in Company

RNS Number : 9994U
Advanced Oncotherapy PLC
28 November 2019
 

28 November 2019

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

Holding in Company

 

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, was informed on 28 November 2019 that Mr Philippe Glatz now has a total interest in 15,659,162 ordinary shares of 25 pence each, equivalent to 6.42% of the Company's issued ordinary share capital.

 

 

 Advanced Oncotherapy plc

www.avoplc.com

 Dr. Michael Sinclair, Executive Chairman

Tel: +44 (0) 20 3617 8728

 Nicolas Serandour, CEO

 

 

 

 

 

 Allenby Capital Limited (Nomad & Broker)

 

 Nick Athanas / Liz Kirchner / Nicholas Chambers

 

 

Tel: +44 (0) 20 7601 6100

 

 

 FTI Consulting (Financial PR & IR)

[email protected]

 Simon Conway / Rob Winder

Tel: +44 (0) 20 3727 1000

 

Notes for Editors

 

About Advanced Oncotherapy Plc - www.avoplc.com

 

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
HOLUWARRKRAAUAA

Quick facts: Advanced Oncotherapy PLC

Price: 26

Market: LSE
Market Cap: £79.66 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: Lloyds ends PPI headache; Sirius Minerals 'is quality' says...

Headlines from the Proactive UK newsroom. Anglo American (LON:AAL) has repeated that Sirius Minerals (LON:SXX) is a “quality” investment which is expected to “fit well” with the FTSE 100 group’s strategy. Anglo, which has made a bid for the firm, says the project in North Yorkshire is...

on 20/2/20